1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trial
Authors:
- H-C. SunHSH-C. Sun
- J. FanJFJ. Fan
- F. ShenFSF. Shen
- J. ZhouJZJ. Zhou
- T. SongTST. Song
- X. BaiXBX. Bai
- Y. ZengYZY. Zeng
- M. ChenMCM. Chen
- Z. HuangZHZ. Huang
- M. KuangMKM. Kuang
- J. CaiJCJ. Cai
- J. GaoJGJ. Gao
- 6 November 2025
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 36, S821